Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGXNASDAQ:GTHNASDAQ:NTRANASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$179.36-0.2%$176.12$136.35▼$182.38$20.05B0.49993,853 shs850,341 shsGTHGenetron$4.03$3.98$2.08▼$4.05$127.27M0.5151,662 shs412,603 shsNTRANatera$160.72-4.9%$159.78$92.14▼$183.00$23.07B1.731.42 million shs1.36 million shsRDNTRadNet$55.62-2.3%$56.28$45.00▼$93.65$4.27B1.41682,058 shs720,330 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.01%-0.12%+3.73%+5.95%+31.15%GTHGenetron0.00%0.00%0.00%-0.12%-0.12%NTRANatera+0.58%-0.84%+8.21%+20.11%+56.01%RDNTRadNet-0.37%+3.72%-1.51%+12.43%-3.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDGXQuest Diagnostics4.9559 of 5 stars2.34.04.24.73.52.52.5GTHGenetronN/AN/AN/AN/AN/AN/AN/AN/ANTRANatera2.12 of 5 stars2.52.00.00.03.52.50.6RDNTRadNet4.2149 of 5 stars3.82.00.04.62.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.69Moderate Buy$185.733.55% UpsideGTHGenetron 0.00N/AN/AN/ANTRANatera 3.00Buy$184.6314.87% UpsideRDNTRadNet 3.50Strong Buy$69.6025.13% UpsideCurrent Analyst Ratings BreakdownLatest RDNT, GTH, DGX, and NTRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$69.006/12/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/6/2025DGXQuest DiagnosticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$180.00 ➝ $190.004/28/2025DGXQuest DiagnosticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$180.00 ➝ $200.004/23/2025DGXQuest DiagnosticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$182.00 ➝ $190.004/23/2025DGXQuest DiagnosticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetIn-Line ➝ In-Line$175.00 ➝ $180.004/23/2025DGXQuest DiagnosticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$175.00 ➝ $185.004/23/2025DGXQuest DiagnosticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$191.00 ➝ $194.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$9.87B2.03$13.49 per share13.30$61.38 per share2.92GTHGenetron$94.34M1.35N/AN/A$2.63 per share1.53NTRANatera$1.70B12.93N/AN/A$9.05 per share17.76RDNTRadNet$1.83B2.28$3.40 per share16.34$15.31 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$871M$7.9122.6817.102.518.81%15.11%6.65%7/22/2025 (Estimated)GTHGenetron-$117.21MN/A0.00∞N/AN/AN/AN/AN/ANTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)RDNTRadNet$2.79M-$0.43N/A104.94N/A-1.73%1.41%0.48%8/6/2025 (Estimated)Latest RDNT, GTH, DGX, and NTRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025DGXQuest Diagnostics$2.56N/AN/AN/A$2.73 billionN/A5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million4/22/2025Q1 2025DGXQuest Diagnostics$2.15$2.21+$0.06$1.94$2.63 billion$2.65 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.201.78%N/A40.46%14 YearsGTHGenetronN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ALatest RDNT, GTH, DGX, and NTRA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/14/2025DGXQuest Diagnosticsquarterly$0.801.86%7/7/20257/7/20257/21/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.841.441.31GTHGenetronN/AN/AN/ANTRANateraN/A3.873.74RDNTRadNet0.872.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%GTHGenetron10.74%NTRANatera99.90%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics8.16%GTHGenetronN/ANTRANatera7.60%RDNTRadNet5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics56,000111.64 million102.53 millionOptionableGTHGenetron99331.62 millionN/ANot OptionableNTRANatera4,434136.55 million126.17 millionOptionableRDNTRadNet11,02175.03 million70.83 millionOptionableRDNT, GTH, DGX, and NTRA HeadlinesRecent News About These CompaniesAllspring Global Investments Holdings LLC Boosts Position in RadNet, Inc. (NASDAQ:RDNT)June 29 at 5:32 AM | marketbeat.comRadNet (NASDAQ:RDNT) Lowered to "Sell" Rating by Wall Street ZenJune 29 at 3:22 AM | marketbeat.comSequoia Financial Advisors LLC Takes Position in RadNet, Inc. (NASDAQ:RDNT)June 28 at 4:11 AM | marketbeat.comBessemer Group Inc. Buys 40,745 Shares of RadNet, Inc. (NASDAQ:RDNT)June 27, 2025 | marketbeat.comEarly Detection Revolution: RadNet implements AI into low-dose CTJune 23, 2025 | ladowntownnews.comLSG Americas Securities LLC Raises Position in RadNet, Inc. (NASDAQ:RDNT)June 22, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded by Wall Street Zen to "Hold" RatingJune 22, 2025 | americanbankingnews.comRadNet (NASDAQ:RDNT) Upgraded at Wall Street ZenJune 21, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Might Be Having Difficulty Using Its Capital EffectivelyJune 20, 2025 | finance.yahoo.comRadNet, Inc. (NASDAQ:RDNT) Given Consensus Rating of "Strong Buy" by AnalystsJune 15, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Upgraded by B. Riley to Strong-Buy RatingJune 14, 2025 | marketbeat.comRadNet (NASDAQ:RDNT) Coverage Initiated by Analysts at B. RileyJune 13, 2025 | marketbeat.com1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Be Wary OfJune 12, 2025 | msn.comRadNet, Inc. Secures $100 Million Incremental Term Loan to Support Strategic Growth InitiativesJune 11, 2025 | quiverquant.comQRadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate InitiativesJune 11, 2025 | globenewswire.comGAMMA Investing LLC Buys 80,396 Shares of RadNet, Inc. (NASDAQ:RDNT)June 11, 2025 | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) is Harbor Capital Advisors Inc.'s 4th Largest PositionJune 10, 2025 | marketbeat.comE. Ohman J or Asset Management AB Buys 5,300 Shares of RadNet, Inc. (NASDAQ:RDNT)June 7, 2025 | marketbeat.comRDNT Q1 Earnings Call: Severe Weather Disruptions and Ongoing Shift to Advanced Imaging Highlight ResultsJune 6, 2025 | msn.comRadNet Acquires See-Mode Technologies to Enhance AI Ultrasound ImagingJune 5, 2025 | insidermonkey.comRadNet Acquires Ultrasound Firm See-Mode TechnologiesJune 4, 2025 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the Strength3 Stocks Hitting All-Time Highs With More Room to RunBy Dan Schmidt | June 27, 2025View 3 Stocks Hitting All-Time Highs With More Room to RunGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingAlphabet’s Comeback: The Hidden Engines Powering GoogleBy Ryan Hasson | June 23, 2025View Alphabet’s Comeback: The Hidden Engines Powering GoogleIBM Up 10 Days in a Row: What’s Driving the Winning Streak?By Dan Schmidt | June 13, 2025View IBM Up 10 Days in a Row: What’s Driving the Winning Streak?RDNT, GTH, DGX, and NTRA Company DescriptionsQuest Diagnostics NYSE:DGX$179.36 -0.27 (-0.15%) Closing price 03:59 PM EasternExtended Trading$181.26 +1.90 (+1.06%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Genetron NASDAQ:GTHGenetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.Natera NASDAQ:NTRA$160.72 -8.22 (-4.87%) Closing price 04:00 PM EasternExtended Trading$160.70 -0.02 (-0.01%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.RadNet NASDAQ:RDNT$55.62 -1.29 (-2.27%) Closing price 04:00 PM EasternExtended Trading$55.62 +0.01 (+0.01%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
